Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TICS Trial of lyophilized fecal microbiota capsules in children with IBS
NL-OMON58424Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of lyophilized allogeneic fecal microbiota in irritable bowel syndrome (IBS) and functional abdominal pain syndrome (CAPS) (2 arms), sponsored by Amsterdam University Medical Center. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
lyophilized allogeneic fecal microbiota
03
Conditions
irritable bowel syndrome (IBS)functional abdominal pain syndrome (CAPS)
Beyond the preview
Go deeper on NL-OMON58424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58424.